PE20250605A1 - Derivados de pirido-[3,4-d]piridazina amina utiles como derivados de nlrp3 - Google Patents

Derivados de pirido-[3,4-d]piridazina amina utiles como derivados de nlrp3

Info

Publication number
PE20250605A1
PE20250605A1 PE2024002059A PE2024002059A PE20250605A1 PE 20250605 A1 PE20250605 A1 PE 20250605A1 PE 2024002059 A PE2024002059 A PE 2024002059A PE 2024002059 A PE2024002059 A PE 2024002059A PE 20250605 A1 PE20250605 A1 PE 20250605A1
Authority
PE
Peru
Prior art keywords
alkyl
nlrp3
compounds
halogen
pyrido
Prior art date
Application number
PE2024002059A
Other languages
English (en)
Spanish (es)
Inventor
Stephane Dorich
Amandine Chefson
Stephane Ciblat
Original Assignee
Ventus Therapeutics U S Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/704,983 external-priority patent/US11618751B1/en
Application filed by Ventus Therapeutics U S Inc filed Critical Ventus Therapeutics U S Inc
Publication of PE20250605A1 publication Critical patent/PE20250605A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2024002059A 2022-03-25 2023-03-24 Derivados de pirido-[3,4-d]piridazina amina utiles como derivados de nlrp3 PE20250605A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17/704,983 US11618751B1 (en) 2022-03-25 2022-03-25 Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US202263420930P 2022-10-31 2022-10-31
US202363443874P 2023-02-07 2023-02-07
PCT/US2023/064967 WO2023183943A1 (en) 2022-03-25 2023-03-24 Pyrido-[3,4-d]pyridazine amine derivatives useful as nlrp3 derivatives

Publications (1)

Publication Number Publication Date
PE20250605A1 true PE20250605A1 (es) 2025-02-26

Family

ID=86329581

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024002059A PE20250605A1 (es) 2022-03-25 2023-03-24 Derivados de pirido-[3,4-d]piridazina amina utiles como derivados de nlrp3

Country Status (13)

Country Link
EP (1) EP4499638A1 (https=)
JP (1) JP2025510414A (https=)
KR (1) KR20250005125A (https=)
CN (1) CN119137121A (https=)
AU (1) AU2023238121A1 (https=)
CA (1) CA3246681A1 (https=)
CL (1) CL2024002855A1 (https=)
CO (1) CO2024013702A2 (https=)
IL (1) IL315842A (https=)
MX (1) MX2024011697A (https=)
PE (1) PE20250605A1 (https=)
TW (1) TW202345836A (https=)
WO (1) WO2023183943A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
TW202313577A (zh) 2021-06-04 2023-04-01 瑞士商赫孚孟拉羅股份公司 新穎化合物
US12331048B2 (en) * 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
KR20250106322A (ko) * 2022-12-28 2025-07-09 장춘 진사이언스 파마슈티컬 씨오., 엘티디. 피리다진계 nlrp3 억제제 화합물, 약학 조성물 및 이의 제조 방법과 용도
WO2025059481A1 (en) 2023-09-13 2025-03-20 Ventus Therapeutics U.S., Inc. Solid forms of an nlrp3 inhibitor and uses thereof
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119731A1 (es) * 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
US11618751B1 (en) * 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) * 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
CR20240093A (es) * 2021-08-25 2024-05-23 Ptc Therapeutics Inc Inhibidores de NLRP3

Also Published As

Publication number Publication date
MX2024011697A (es) 2024-11-08
JP2025510414A (ja) 2025-04-14
IL315842A (en) 2024-11-01
CA3246681A1 (en) 2023-09-28
CN119137121A (zh) 2024-12-13
WO2023183943A1 (en) 2023-09-28
KR20250005125A (ko) 2025-01-09
TW202345836A (zh) 2023-12-01
CO2024013702A2 (es) 2024-11-08
CL2024002855A1 (es) 2025-02-14
AU2023238121A1 (en) 2024-10-10
EP4499638A1 (en) 2025-02-05

Similar Documents

Publication Publication Date Title
PE20250605A1 (es) Derivados de pirido-[3,4-d]piridazina amina utiles como derivados de nlrp3
ES2799892T3 (es) Sales de xantilio 3,6-disustituidas
US8598383B2 (en) Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases
AR039673A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metodos para su aplicacion
AR060432A1 (es) Tetrahidropteridinas utiles como inhibidores de las proteinas quinasas
AR056762A1 (es) (4 -(6-halo-7- substituidos -2,4- dioxo-1,4- dihidro-2h-quinazolin-3-il- fenil)-5- cloro- tiophen-2- il sulfonilureas y formas y metodos
AR129937A1 (es) Derivados de 1,3,4-oxadiazol como inhibidores selectivos de histona desacetilasa 6
ITMI20010985A1 (it) Farmaci per il morbo di alzheimer
PE20251252A1 (es) Derivados de oxoindolinil amida para inhibir nlrp3 y usos de los mismos
AR016644A1 (es) Compuestos de 2-aminopiridinas con sustituyentes alcoxi ramificados, composicion farmaceutica y uso para la manufactura de medicamentos
ECSP22082217A (es) Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida
CO6180505A2 (es) Metodos para el tratamiento de transtornos cocleares y vestibulares
JP2020509043A (ja) カンナビノイドアゴニストによる認知症の治療
CO2022015823A2 (es) Derivados de n-(piperidin-4-il)benzamida de acción luminal
ES2396764B1 (es) FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES.
AR127255A1 (es) NUEVOS DERIVADOS DE BENZODIAZEPINA COMO GABAA g1 PAM
CO2025010159A2 (es) Derivados de 3-(2-(dimetilamino)etil)-1h-indol-4-ilo
KR101189751B1 (ko) 세포 손상 및 염증 질환의 치료 또는 예방용 약학 조성물
ES2222370T3 (es) Derivados de disulfuro de anilina para tratar enfermedades alergicas.
AR016672A1 (es) Ligandos del receptor h3 del tipo fenil-alquil-imidazoles, composicion farmaceutica que los contiene y el uso de los mismos para la manufactura de unmedicamento
AR127321A1 (es) Inhibidores de la monoacilglicerol lipasa (magl)
AR128498A1 (es) Procesos novedosos
RU2007128964A (ru) Антагонисты рецепторов 5-ht7
ES2243482T3 (es) Composiciones que contienen un derivado de disulfuro de benzamida para tratar enfermedades alergicas.
GEAP202516640A (en) Crystal form of a pde4 inhibitor